Search Results

There are 5313 results for: content related to: Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease

  1. You have free access to this content
    Rivastigmine for Alzheimer's disease

    Intervention Review

    The Cochrane Library

    Jacqueline S Birks, Lee Yee Chong and John Grimley Evans

    Published Online : 22 SEP 2015, DOI: 10.1002/14651858.CD001191.pub4

  2. Cholinesterase inhibitors for Alzheimer's disease

    Intervention Review

    The Cochrane Library

    Jacqueline S Birks

    Published Online : 25 JAN 2006, DOI: 10.1002/14651858.CD005593

  3. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer’s disease

    International Journal of Clinical Practice

    Volume 65, Issue 4, April 2011, Pages: 465–471, G. T. Grossberg, J. T. Olin, M. Somogyi and X. Meng

    Version of Record online : 11 FEB 2011, DOI: 10.1111/j.1742-1241.2011.02641.x

  4. You have free access to this content
    Rivastigmine for vascular cognitive impairment

    Intervention Review

    The Cochrane Library

    Jacqueline Birks, Bernadette McGuinness and David Craig

    Published Online : 31 MAY 2013, DOI: 10.1002/14651858.CD004744.pub3

  5. Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease

    CNS Neuroscience & Therapeutics

    Volume 16, Issue 4, August 2010, Pages: 246–253, Murat Emre, Roberto Bernabei, Rafael Blesa, Roger Bullock, Luis Cunha, Hugo Daniëls, Edward Dziadulewicz, Hans Förstl, Lutz Frölich, Tomasz Gabryelewicz, Oleg Levin, James Lindesay, Pablo Martínez-Lage, Andreas Monsch, Magda Tsolaki and Teus Van Laar

    Version of Record online : 29 MAR 2010, DOI: 10.1111/j.1755-5949.2010.00141.x

  6. You have free access to this content
    Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease

    International Journal of Clinical Practice

    Volume 69, Issue 5, May 2015, Pages: 518–530, G. Alva, J. L. Cummings, J. E. Galvin, X. Meng and D. M. Velting

    Version of Record online : 16 FEB 2015, DOI: 10.1111/ijcp.12621

  7. Similar Rivastigmine Pharmacokinetics and Pharmacodynamics in Japanese and White Healthy Participants Following the Application of Novel Rivastigmine Patch

    The Journal of Clinical Pharmacology

    Volume 49, Issue 4, April 2009, Pages: 430–443, Dr Gilbert Lefèvre, Ms Monika Büche, Dr Greg Sedek, Mr Steve Maton, Dr Albert Enz, Dr Ulrike Lorch, Dr Cyriaque Sagan and Dr Silke Appel-Dingemanse

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270008330161

  8. Pharmacokinetics and Bioavailability of the Novel Rivastigmine Transdermal Patch Versus Rivastigmine Oral Solution in Healthy Elderly Subjects

    The Journal of Clinical Pharmacology

    Volume 48, Issue 2, February 2008, Pages: 246–252, Dr Gilbert Lefèvre, Mrs Françoise Pommier, Dr Greg Sędek, Dr Mark Allison, Dr Hsun-Lun Aaron Huang, Mrs Beate Kiese, Dr Yu-Yun Ho and Dr Silke Appel-Dingemanse

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007312154

  9. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment

    International Journal of Clinical Practice

    Volume 60, Issue 1, January 2006, Pages: 110–118, T. Dantoine, 1 S. Auriacombe, 2 M. Sarazin, 3 H. Becker, 4 J-J Pere and 5 I. Bourdeix 5

    Version of Record online : 20 DEC 2005, DOI: 10.1111/j.1368-5031.2005.00769.x

  10. Absorption of Rivastigmine from Different Regions of the Gastrointestinal Tract in Humans

    The Journal of Clinical Pharmacology

    Volume 44, Issue 6, June 2004, Pages: 599–604, Dr. Lucy Lee, Dr. Mohammad Hossain, Dr. Yanfeng Wang and Dr. Greg Sedek

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270004265645

  11. You have free access to this content
    CaMKII activity is essential for improvement of memory-related behaviors by chronic rivastigmine treatment

    Journal of Neurochemistry

    Volume 128, Issue 6, March 2014, Pages: 927–937, Shigeki Moriguchi, Hideaki Tagashira, Yuzuru Sasaki, Jay Z. Yeh, Hiroyuki Sakagami, Toshio Narahashi and Kohji Fukunaga

    Version of Record online : 17 NOV 2013, DOI: 10.1111/jnc.12510

  12. You have free access to this content
    Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand

    Psychogeriatrics

    Volume 13, Issue 1, March 2013, Pages: 1–8, Kongkiat KULKANTRAKORN, Panas TANYAKITPISAL, Somchai TOWANABUT, Charungthai DEJTHEVAPORN, Poonsri RANGSEEKAJEE, Sunsanee PONGPAKDEE, Somsak LAPTIKULTHAM, Kritsada RODPRASERT, Suwanna SETTHAWATCHARAWANICH and Bandit THINKHAMROP

    Version of Record online : 17 FEB 2012, DOI: 10.1111/j.1479-8301.2012.00403.x

  13. Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias

    International Journal of Clinical Practice

    Volume 60, Issue 6, June 2006, Pages: 639–645, C Ballard, R Lane, P Barone, R Ferrara and S Tekin

    Version of Record online : 24 MAY 2006, DOI: 10.1111/j.1368-5031.2006.00967.x

    Corrected by:

    Erratum

    Vol. 60, Issue 9, 1146, Version of Record online: 10 AUG 2006

  14. Rivastigmine, a New-Generation Cholinesterase Inhibitor for the Treatment of Alzheimer's Disease

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 20, Issue 1, January 2000, Pages: 1–12, Michael W. Jann

    Version of Record online : 17 JAN 2012, DOI: 10.1592/phco.20.1.1.34664

  15. What are the benefits and harms of rivastigmine for Alzheimer's disease?

    Cochrane Clinical Answers

    Published Online: 16 MAR 2016, DOI: 10.1002/cca.794
  16. Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study

    International Journal of Clinical Practice

    Volume 58, Issue 4, April 2004, Pages: 346–353, R. Moretti, 1,2 P. Torre, 2 R.M. Antonello, 2 G. Cazzato, 2 S. Griggio, 2 M. Ukmar and 3 A. Bava 1

    Version of Record online : 29 APR 2004, DOI: 10.1111/j.1368-5031.2004.00127.x

  17. Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo-controlled study

    Movement Disorders

    Volume 30, Issue 7, June 2015, Pages: 912–918, Eugenia Mamikonyan, Sharon X. Xie, Emilie Melvin and Daniel Weintraub

    Version of Record online : 25 APR 2015, DOI: 10.1002/mds.26236

  18. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials

    International Journal of Clinical Practice

    Volume 64, Issue 2, January 2010, Pages: 188–193, C. H. Sadowsky, M. R. Farlow, X. Meng and J. T. Olin

    Version of Record online : 11 DEC 2009, DOI: 10.1111/j.1742-1241.2009.02253.x

  19. A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry

    Rapid Communications in Mass Spectrometry

    Volume 20, Issue 22, 30 November 2006, Pages: 3330–3336, Suzanne V. Frankfort, Mariët Ouwehand, Maria J. van Maanen, Hilde Rosing, Linda R. Tulner and Jos H. Beijnen

    Version of Record online : 17 OCT 2006, DOI: 10.1002/rcm.2737

  20. You have free access to this content
    Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions

    Psychogeriatrics

    Volume 12, Issue 3, September 2012, Pages: 165–171, Peter PREGELJ

    Version of Record online : 20 SEP 2012, DOI: 10.1111/j.1479-8301.2011.00400.x